LungLife AI, Inc. (LLA.L) Research

Headquartered in Thousand Oaks, California, and established in 2009, LungLife AI, Inc. is a diagnostics firm dedicated to creating AI-powered clinical solutions for lung cancer. The company, which was known as Cynvenio Biosystems, Inc. until its renaming in May 2019, operates in both the United States and China. Its primary focus involves the ongoing development of LungLB, a blood test engineered to differentiate between cancerous and non-cancerous lung nodules initially discovered through CT scans.

Market snapshot

Symbol
LLA.L
Price
$5.00
Day change
0.00%
Market cap
$1.3M
52-week range
0.05-30
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Cel AI PLC (CLAI.L)
  • DeepVerge plc (DVRG.L)
  • Hellenic Dynamics Plc (HELD.L)
  • Kanabo Group Plc (KNB.L)
  • LungLife AI, Inc. (LLAI.L)
  • Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
  • Oncimmune Holdings plc (ONC.L)
  • Ovoca Bio plc (OVB.L)

Open LungLife AI, Inc. (LLA.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.